The results of acute exacerbation of chronic C hepatitis among Mongolian adults with B-Non-Hodgkin Lymphoma
- VernacularTitle:В эсийн Ходжкины бус Лимфомтой насанд хүрэгчдийн дунд архаг С хепатитийн хурц сэдрэлийг судалсан дүн
- Author:
Myagmarjav B
1
;
Delgerbat B
1
;
Khishigjargal B
2
;
Myadagsuren S
2
;
Oyundelger N
2
;
Altankhuu M
1
;
Erdenetsogt D
3
;
Dahgwahdorj Ya
1
;
Davaadorj D
3
;
Naranjargal D
1
Author Information
1. Liver Center, Ulaanbaatar, Mongolia
2. First Central Hospital of Mongolia
3. Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
- Publication Type:Journal Article
- Keywords:
Acute exacerbation;
chemotherapy;
chronic hepatitis C;
non-Hodgkin Lymphoma
- From:Mongolian Medical Sciences
2019;189(3):16-21
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:
Chemotherapy-related acute exacerbation or hepatitis flares related to HCV positive B cell non-Hodgkin’s lymphoma (B-NHL) is one of the significant clinical issues
Material and Method:We studied anti-HCV incidences among patients newly diagnosed with B-NHL, from 2015 to 2018. Survey data were collecting from medical history, electronic medical record system of First Central Hospital
was acquired and collected according to the research ethics (approved by Ethics Committee of Ministry
of Health, No.4 on June 19, 2017). Also, cases of chemotherapy-related acute exacerbation (AE) for
HCV-RNA positive cases were studied. Student’s t-test or nonparametric statistics were utilized to test
for statistically significant differences in continuous variables, whereas the chi-square or Fisher’s exact
test was used for categorical variables. p<0.05 was considered statistically significant.
Results:The study showed that 39.5% of 233 cases with B-NHL are anti-HCV positive. Anti-HCV positive prevalence among B-NHL subjects was significantly higher compared to the general population. Chemotherapy-related AE occurred in 21.05% for the anti-HCV positive group and 36.36% for HCV-RNA positive group. Furthermore, before chemotherapy alanine aminotransferase (ALT) median was 15.2 for the group without AE, whereas it was 48.2 for the group with AE (p<0.01).
Conclusions:Our study showed that the prevalence of anti-HCV positive among B-NHL patients was significantly
higher than the general population prevalence. For all cases of AE, HCV-RNA was positive, and these
patients were treated with only chemotherapy without any anti-viral treatment. Anti-viral therapy needs to
be introduced urgently to prevent AE since liver fibrosis is aggravated quickly after AE.
- Full text:2019-189(3)-16-21.pdf
